NEW YORK – Immune cell sequencing firm Adaptive Biotechnologies said after the close of the market on Thursday that it is selling 8 million shares of common stock at $26.50 per share.
The firm is selling the shares on behalf of certain investors and will not receive any proceeds from the sale.